Talazoparib (Talzenna®) in combination with enzalutamide for mCRPC. HTA ID: 23074

Assessment Status Rapid Review Complete
HTA ID 23074
Drug Talazoparib
Brand Talzenna®
Indication Talazoparib (Talzenna®) in combination with enzalutamide is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Assessment Process
Rapid review commissioned 07/12/2023
Rapid review completed 21/12/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that talazoparib in combination with enzalutamide not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.